Boston Scientific Corporation $BSX Holdings Increased by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. grew its stake in Boston Scientific Corporation (NYSE:BSX) by 9.7% during the third quarter, HoldingsChannel.com reports. The firm owned 207,191 shares of the medical equipment provider’s stock after buying an additional 18,381 shares during the period. Salem Investment Counselors Inc.’s holdings in Boston Scientific were worth $9,044,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Boston Scientific in the second quarter valued at about $5,534,781,000. Primecap Management Co. CA acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $2,156,233,000. Janus Henderson Group PLC grew its position in shares of Boston Scientific by 5.2% during the 4th quarter. Janus Henderson Group PLC now owns 12,589,385 shares of the medical equipment provider’s stock worth $1,200,404,000 after buying an additional 617,515 shares during the period. Amundi increased its stake in shares of Boston Scientific by 13.8% in the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after acquiring an additional 1,707,754 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after acquiring an additional 2,856,040 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 1.2%

BSX opened at $43.33 on Wednesday. The stock has a market capitalization of $62.79 billion, a P/E ratio of 17.54, a P/E/G ratio of 1.05 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $41.38 and a 12 month high of $105.65. The firm’s fifty day simple moving average is $46.35 and its 200 day simple moving average is $50.16. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.25 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, Director Edward Ludwig acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director David Habiger bought 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 194,522 shares of company stock valued at $9,385,210 over the last three months. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on BSX shares. Wells Fargo & Company lowered their target price on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 23rd. Piper Sandler reduced their target price on Boston Scientific from $65.00 to $60.00 in a report on Wednesday, July 29th. Sanford C. Bernstein reissued an “outperform” rating and issued a $54.00 target price (down from $60.00) on shares of Boston Scientific in a research note on Saturday, October 3rd. Robert W. Baird set a $56.00 price target on Boston Scientific in a report on Thursday, July 30th. Finally, Canaccord Genuity Group cut their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $68.43.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.